Atopic Dermatitis | LEO Pharma | LP0162-1337
Pharmaceutical Company/Sponsor:
LEO Pharma
Code:
LP0162-1337
Title:
An Open-label, Single-arm, Multi-centre, Long-term Extension Trial to Evaluate the Safety and Efficacy of Tralokinumab in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Clinical Trials
Type:
Interventional
Phase:
3
Condition/Disease:
Atopic Dermatitis
Intervention(s)/Treatment(s):
Drug: Tralokinumab
Status:
Recruiting
Link for Additional Information:
